FDA approves Norditropin FlexPro PenMate (somatropin injection) for growth-hormone treatment- Novo Nordisk
Novo Nordisk announced FDA approval of FlexPro PenMate, designed for users of Norditropin FlexPro (somatropin injection) 5 mg, 10 mg, and 15 mg pens who dislike needles and prefer them to be hidden during the injection process, for people with growth hormone-related disorders. FlexPro PenMate has been developed exclusively for use with the Norditropin FlexPro 5, 10, and 15 mg pens. It is a cylindrical attachment that is designed to conceal the needle so patients cannot see it being inserted into their skin during injection.
The Norditropin FlexPro pen slides into FlexPro PenMate and twists into a locked position. The needle is then attached, and the injection process can begin. FlexPro PenMate features a large gripping surface so patients can firmly hold the pen during injection. Norditropin FlexPro is the only prefilled growth hormone injection pen that can be stored outside of the refrigerator for up to 21 days after first use.
Comment: Norditropin FlexPro was first approved by the FDA in 2000.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins